Allogene Therapeutics, Inc. Common Stock (ALLO)

Price$1.88

Value ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)20.84%

Price vs S&P 500 (4W)-17.53%

VGM Score37.01

Market Capitalization$648.89M

All Metrics

Book Value / Share (Quarterly)$1.14

P/TBV (Annual)3.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-91.70%

Cash Flow / Share (Quarterly)$-0.45

Price vs S&P 500 (YTD)29.07%

Net Profit Margin (TTM)-269835.03%

EPS (TTM)$-0.87

10-Day Avg Trading Volume7.67M

EPS Excl Extra (TTM)$-0.87

EPS (Annual)$-0.87

ROI (Annual)-65.25%

Net Profit Margin (5Y Avg)-3191.05%

Cash / Share (Quarterly)$1.09

ROA (Last FY)-45.90%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-53.63%

Operating Margin (TTM)-274487.82%

Cash Flow / Share (Annual)$-0.65

P/B Ratio2.33x

P/B Ratio (Quarterly)2.13x

Net Income / Employee (Annual)$-1,272,600

EV / Revenue (TTM)3140.01x

ROA (TTM)-41.63%

EPS Incl Extra (Annual)$-0.87

Current Ratio (Annual)7.93x

Quick Ratio (Quarterly)9.47x

3-Month Avg Trading Volume8.72M

52-Week Price Return45.74%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$7.68

P/S Ratio (Annual)29495.03x

Asset Turnover (Annual)0.00x

52-Week High$4.46

Operating Margin (5Y Avg)-3267.44%

EPS Excl Extra (Annual)$-0.87

CapEx CAGR (5Y)-64.23%

26-Week Price Return28.77%

Quick Ratio (Annual)7.74x

13-Week Price Return-18.61%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.65x

Enterprise Value$618.58M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-30.18%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1168850.00%

Cash / Share (Annual)$1.09

3-Month Return Std Dev100.27%

Net Income / Employee (TTM)$-1,272,600

ROE (Last FY)-65.25%

EPS Basic Excl Extra (Annual)$-0.87

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.87

Receivables Turnover (Annual)0.01x

ROI (TTM)-57.07%

P/S Ratio (TTM)3293.86x

Pretax Margin (5Y Avg)-3192.20%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.68

Price vs S&P 500 (52W)21.37%

Year-to-Date Return37.23%

5-Day Price Return-12.56%

EPS Normalized (Annual)$-0.87

ROA (5Y Avg)-41.84%

Net Profit Margin (Annual)-1170863.64%

Month-to-Date Return-13.36%

Cash Flow / Share (TTM)$-2.12

EBITD / Share (Annual)$-0.89

Operating Margin (Annual)-1241813.64%

ROI (5Y Avg)-53.63%

EPS Basic Excl Extra (TTM)$-0.87

P/TBV (Quarterly)3.28x

P/B Ratio (Annual)1.05x

Pretax Margin (TTM)-269835.03%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)-26.87%

Beta0.50x

Revenue / Share (TTM)$0.00

ROE (TTM)-57.07%

52-Week Low$0.98

vGradeD

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.18est. -0.19

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

4.20

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALLOAllogene Therapeutics, Inc. Common Stock	D	—	C	$1.88
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf allogeneic CAR T-cell therapies for cancer and autoimmune diseases. Its genetically engineered, donor-derived T-cell products offer broader patient eligibility and manufacturing scalability compared to autologous therapies. The pipeline targets lymphoma, leukemia, solid tumors, and autoimmune disorders, with revenue generated from collaborations and licensing agreements.